Alliance for Hippocratic Medicine, et al.,
Plaintiffs-Appellees
v.
Food & Drug Administration, et al.,
Defendants-Appellants
Danco Laboratories, LLC
Intervenor-Defendant-Appellant

On Appeal from the United States District Court
Amarillo Division, No. 2:22-CV-223-Z

AMICI CURIAE

Thomas S. Leatherbury
THOMAS S. LEATHERBURY LAW, PLLC
Cumberland Hill School Building
1901 N. Akard St
Dallas, TX 75201
Tel.: (214) 258-1304
Tom@tsleatherburylaw.com

Counsel for Amici Curiae
Doctors for America and
The Reproductive Medicine Alliance

1. No. 23-10362, Alliance for Hippocratic Medicin
   Admini, settra alt.ion
2. The undersigned counsel of record certifies that the following listed persons and entities as described in the fourth sentence of Appellant's Certif
   following listed persons or entities as d
   Fifth Circuit Rule 28.2.1 have an interest in the outcome of
   representations are made so that the judges
   possible disqualification or recusal.

Amici Curiae
Doctors for America
The Reproductive Health Coalition

Attorneys for Amici Curiae
Thomas S. Leatherbury
Thomas S. Leatherbury Law, PLLC
Christopher J. Morten
Columbia Law School Science, Health & Information

No publicly traded company has an ownership int
listed above.

Respectfully submitted
/s/ Thomas S. Leatherbury
Thomas S. Leatherbury
Counsel for Amici Curia
American Reproductive H
Coalition

TABLE OF CONTENTS ..... i i

TABLE OF AUTHORITIES..... i i i

I. INTEREST OF AMICI CURIAE 1

II.

SAUL D. HOFFMAN & REBECCA A. MAYNARD, KIDS HAVING KIDS: ECONOMIC COSTS AND SOCIAL CONSEQUENCES OF TEEN PREGNANCY (2d ed. 2008) 14

Katherine Kortsmit et al., Abortion Surveillance — United States, 2019, 70 MMWR SURVEILLANCE SUMMARIES 1 14

Lawrence Lee et al., Cannabis for pre-existing medical conditions and cannabis initiated for adverse effects integrated into medical practices that do not require authorization, 76 CONTRACEPTION 96 7

Man-Wa Lui & Pak-Chung Ho, First trimester termination, 63 BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY 13 (2020) 6

Honor Macnaughton, Melissa Nothnagle & Jessica Cwiak, Misoprostol for Early Pregnancy, 103 AM. FAM. PHYSICIAN 473 8

Andrea Park, Abortion Restriction Does Not Curtail Suicide, MEDPAGE TODAY 15

Rachel H. Phelps, Eric A. Schaff, Stephen J. Eisele & Alison G. Min, 64(6) CONTRACEPTION 339, 339 (2001) 14

Reshma Ramachandran, Written Testimony of Reshma Ramachandran, M.D., M.P.H. at Hearing on "FDA Use of Real-World Evidence to Support Effectiveness of Approved Drugs and Biologics" Subcommittee 1

Ami Doo ic t o r s f o r Am e r Thc ae (Rñe DE Aròo) adnudc Ctoia v ie Hie a l nt

(ñ RHC ò) f i l e t h i s Am i c u s B r i e - f Api m e s l u l pa p o s r ô e m e D r e

regulatory reform through legislation, public education campaigns, policymakers, and more. For example, DFAôs FDA Task testified, and met with policymakers to advoca User Fee Act (PDUFA) to make user fee agreements in order to ensure timely access to drugs and bio and safe.[2] Recently, the FDA Task Force has also advoca miscarriage management as an indication to mifepris to the safest and most effective treatments f choice in miscarriage management.[3]ò

The RHC comprises a wide range of medical, scie allied organizations, collectively represe advocate with a unified voice to protect acces founded in June 2022 by the executive leadership American Medical Womenôs Association. The RHC

---

[2] Written Testimony of Reshma Ramachandran, M.D., M Reauthorization: Ensuring Safe and Effective Drug DOCTORS FOR AMERICA (2022), https://doctorsforamerica.org/wp-content/uploads/2022/10/Written-Testimony-for-House-Energy-and-Commerce-Committee-Hearing-on-Reauthorization-of-Essential-Drug-User-Fee-Programs-by-Reshma-Ramachandran-MD-MPH-FACOG-Doctors-for-America.pdf (last visited Feb. 7, 2023).

[3] The terms ñmiscarriageò and ñearly pregnancy lossò are See, e.g., AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS, Practice Bulletin No. 200 Loss, 132 OBSTETRICS & GYNECOLOGY e197 (2018).

[4] Citizen Petition from American College of Obstetricians a https://emaapr-projects.net/wp-content/uploads/2022/10/American-College-Obstetricians-and-Gynecologists-ACOG-EMAA-website.pdf (last visit 2023).

include Doctors for America, American Medica
Access, American College of Physicians, America
Civic Health, Dar®l Bianosec, ience, Doctors For Fert
Georgia Health Professionals for Reproduct
Professionals Advancing LGBTQ+ Equality, Health
Pelvic Pain Specialists, Medicaln Satu Adsemotsiaftoiro Ch
Practitioners in Womenôs Health, National Coal
Medical Association, Nurses for America, Patie
Shattering Glass, The Inno-ERa, Womse law fi Mrend, Vdoctine
Women in Medicine, Inc. The RHCôs work of doicgunsietsy, o
autonomy, privacy, and the expectation of trust;
protection of the clinicianôs ethical obliga
to comprehensive training; and-based medicine to
policy and practice. The RHC supports the right
the full scope of reproductive healthcare, in

Amici have a strong interest in protecting the autonomy
providers and up-to-date, science-based medicine. Amici submit this brief
highlight the ways in which Texas's abortion laws

United States for [5] osvueprp tow retos stt iyh cyeepr fas, physicians
United States. The stay of mifepristone ôs appr
nationwide, including care for conditions be
management of early pregnancy loss.

Doctaccr so ss the country wish to express to
the potential stay of mifepristone ôs FDA app
ramifications. This amicus brief from [illegible] many practice areas tss cece, y re" e

an unacceptable choice between compliance wi
compliance with the law.

Medical research has consistently demonst
effective and that adverse events and outcome
less than a fraction of one percent of women
been demonstrated through rigorous investi
approval of mifepristone and further confir
literature published after its approval. Stu
approval in 2000 found adverse events requiring
sample size of over 2,000 patients.[8]

Many studies have shown that serious adver
0.5% of medication abortions.[9] Moreover, a
tracked by the FDA reveals that mifepristone ha

an unacceptable choice between compliance wi
compliance with the law.

Medical research has consistently demonst
effective and that adverse events and outcome
less than a fraction of one percent of women
been demonstrated through rigorous investi
approval of mifepristone and further confir
literature published after its approval. Stu
approval in 2000 found adverse events requiring
sample size of over 2,000 patients.[8]

Many studies have shown that serious adver
0.5% of medication abortions.[9] Moreover, a
tracked by the FDA reveals that mifepristone ha

6833/(0(17$/ &(57,),&$7(2) ,17(5(67(' 3(56216

1R $OOLDQFH IRU +LSSRFUDWLF 0HGLFLQH

$GPLQLVWUDWLRQ

7KH XQGHUVLJQHG FRXQVHO RI UHFRUG IRU WKH DPLFL FXULDH KHUHE\ FHUWLILHV WKDW QR SDUW\¶V FRXQVHO DXWKRUHG WKLV EULHI LQ ZKROH RU LQ SDUW DQG QR SHUVRQ RWKHU WKDQ WKH DPLFL FXULDH RU LWV PHPEHUV DXWKRUHG LW ,W IXUWKHU FHUWLILHV WKDW QR SDUW\ KDV FRQWULEXWHG PRQH\ WR IXQG WKH SUHSDUDWLRQ RU VXEPLVVLRQ RI WKLV EULHI

$PLFL &XULDH
'RFWRUV IRU $PHULFD
7KH 5HSURGXFWLYH +HDOWK &RDOLWLRQ

$WWRUQH\V IRU $PLFL &XULDH
7KRPDV 6DWKHUXU\
7KRPDV 6 /HDWKHUXU\ /DZ 3//&
&KULVWRSKHU - 0RUWHQ
&ROXPELD /DZ 6FKRRO 6FLHQFH +HDOWK ,QIRUPD

1R SXEOLF\ WUDGHG FRPSDQ\ KDV DQ RZQHUVKLS

OLVWHG DERYH

5HVSHFWIXOO\ VXEPLWWHG
V7KRPDV 6 /HDWKHUXU\
7KRPDV 6 /HDWKHUXU\
&RXQVHO IRU $PLFL &XULD
$PHULF7KH 5HSURGXFWLYH +
&RDOLWLRQ